swordbio latest

Find the latest news and updates from Sword Bio.

June 19, 2018

BioAgilytix Partners with Sword Bio to Provide Superior Immunoassays

Innovative Detection Platform Provides BioAgilytix Customers with Important Advancement in Sensitivity and Reliability for their Immunoassays

June 19, 2018—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, is expanding its advanced bioanalytical technology suite with the addition of Sword Bio’s detection platform for immunoassays. Sword’s platform represents an important advancement in enzyme immunoassays, providing enhanced sensitivity, precision, and accuracy for the rapid and high performance measurement and quantification of biological markers. The companies will collaborate to meet ever-growing customer needs to further enhance the performance of immunoassays used for biomarkers, immunogenicity, and pharmacokinetics (PK).

Sword Bio’s platform uses a patented technology involving resonance Raman to enhance precise and accurate quantification of analytes in the picogram/milliliter (pg/ml) range. Combined with Sword Bio’s ability to rapidly configure an array of off-the-shelf or proprietary tests to the matrix need, the solution will empower BioAgilytix with the ability to create more sensitive and robust assays faster for their clients.

“Sword’s technology will be of great value to BioAgilytix and our customers, as it enables low detection of analytes and gives our team the ability to quickly increase ELISA sensitivity,” said Afshin Safavi, Founder and Global Chief Scientific Officer of BioAgilytix. “It will further enhance our ability to deliver robust and reliable data from assays that we utilize every day, so that we can help our customers make drug development decisions with confidence.”

“BioAgilytix is a globally respected leader in immunoassays, and we are pleased to be partnering with them in meeting the needs of both our customers,” said David Dingott, President and CEO of Sword Bio. “We are confident that the combination of Sword’s innovative platform and BioAgilytix’s deep scientific expertise will enable research and pharmaceutical organizations to continue to make exciting new drug development breakthroughs.”

###

About Sword Bio
Sword Bio is a cutting-edge biosciences company created in response to the rapidly evolving needs of the research and pharmaceutical communities. Sword Bio provides a next-generation detection platform to life scientists, enabling them to continue advances in medical research, drug discovery, and the provision of health care products and services. Its next-generation detection platform for immunoassays enabling detection of picogram levels of analytes with excellent reproducibility. Sword Bio’ ability to rapidly configure an array of off-the-shelf or proprietary tests to the matrix need ensures that researchers can gain robust results and actionable data fast. For more information, visit www.sworddiagnostics.com.

About BioAgilytix
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.

Media Contact:
Carla Nieser
Vovéo Marketing Group
610.240.0400, x 118
c.nieser@voveo.com